Gilead Sciences, Inc.'s Truvada Can Prevent HIV in Heterosexuals, Centers for Disease Control and Prevention (CDC)

Published: Aug 10, 2012

Gilead Sciences Inc. (GILD)’s anti-AIDS pill Truvada safely and effectively reduces the risk of HIV for healthy people having sexual intercourse, according to the first U.S. Centers for Disease Control and Prevention guidelines on using the drugs for prevention in heterosexuals. Daily use of the pills to prevent HIV infection, known as pre-exposure prophylaxis, or PrEP, should only be used for people who are uninfected and continue to use regular testing and prevention methods, according to the interim guidelines. The Atlanta-based agency plans to release comprehensive guidelines by year-end, said Dawn Smith, lead author of the guidance.

Back to news